Lonza 4D or equal nucleofection system

The FDA Office of Acquisitions and Grants Services, on behalf of the Center for Biologics Evaluation and Research, is conducting a market survey to identify potential vendors capable of supplying a Lonza 4D or equivalent nucleofection system that meets specific technical requirements for research and biologics development. The system must be a newly manufactured unit, not refurbished, and capable of delivering DNA, RNA, and proteins into cell lines and primary human cells using conductive polymer metal-free electrodes to avoid toxic ion release. It must process between 2×10⁴ and 1×10⁷ cells per reaction with a minimum threshold of 2×10⁴ cells per single reaction volume and achieve post-transfection cell viability of up to 90% under manufacturer-recommended conditions. The instrument must employ a specialized electrical waveform to transfect non-dividing cells and include an onboard software database with factory-preprogrammed, validated pulse protocols calibrated specifically for primary human dendritic cells. The vendor must provide a turnkey solution including all hardware, software, computers, and components, with full installation, shipping, and on-site training completed within 120 days of award. Installation must be performed by factory-certified personnel, and the system must be accompanied by comprehensive operations and maintenance manuals and warranty coverage of at least one year, beginning upon FDA acceptance, which includes successful on-site training for three to five users covering system operations, calibration, optimization, troubleshooting, and basic maintenance. The solicitation number is 75F40126SSN134795, and responses must be submitted via email by July 8, 2026, to Suzanne Martella at susan.martella@fda.hhs.gov. The North American Industry Classification System code is 334516, with a small business size standard of 1,000 employees. Respondents must provide their business name, Unique Entity ID, address, website, size status, and information on subcontracting opportunities if applicable. All submissions must demonstrate technical capability with descriptive literature and must not include proprietary, confidential, or classified material, nor contain weblinks. Informational pricing is requested for market research purposes only, as this is not a solicitation for proposals and no contract will be awarded from this announcement. The place of performance is FDA/CBER, Building 52/72, Room 4107, Silver Spring, MD. Vendors must also provide data regarding the place